Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MIN-101 MR Formulation in Healthy Volunteers
NCT02232529Phase 1Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Sep 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of roluperidone in schizophrenia (4 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoints: Pharmacokinetic profile of MIN-101 and its main metabolites and Absolute QT intervals and QT intervals corrected using Fridericia formula. Started Sep 2014; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02232529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232529.